Breast cancer with different prognostic characteristics developing in Danish women using hormone replacement therapy

[1]  M. Pike,et al.  Does menopausal hormone replacement therapy interact with known factors to increase risk of breast cancer? , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  J. Litherland,et al.  Effect of hormone replacement therapy on the pathological stage of breast cancer: population based, cross sectional study , 2000, BMJ : British Medical Journal.

[3]  A. Bamberger,et al.  Biphasic effect of medroxyprogesterone-acetate (MPA) treatment on proliferation and cyclin D1 gene transcription in T47D breast cancer cells , 2000, Breast Cancer Research and Treatment.

[4]  H. Adami,et al.  More about: effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. , 2000, Journal of the National Cancer Institute.

[5]  J. Estève,et al.  Does a better grade of tumour occurring in women under hormone replacement therapy compensate for their lower probability of detection by screening mammography , 2002, Journal of medical screening.

[6]  Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. , 1997, Lancet.

[7]  J. Cuzick,et al.  Hormone replacement therapy and biological aggressiveness of breast cancer , 1997, The Lancet.

[8]  N. Keiding,et al.  Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe , 2004, International journal of cancer.

[9]  M. Amin,et al.  Breast carcinoma in pregnant women: Assessment of clinicopathologic and immunohistochemical features , 2004 .

[10]  P. Smith,et al.  Histopathology of breast cancer in relation to age. , 1997, British Journal of Cancer.

[11]  D. Wallwiener,et al.  Tibolone versus 17beta-estradiol/norethisterone: effects on the proliferation of human breast cancer cells. , 2002, European journal of gynaecological oncology.

[12]  Y. Hundrup,et al.  Use of hormone replacement therapy among danish nurses at increased risk of osteoporosis , 2003, International journal of behavioral medicine.

[13]  D. Miglioretti,et al.  Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  H. Olsson,et al.  Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden , 2003, Cancer.

[15]  P. Tan,et al.  Progesterone induces cellular differentiation in MDA-MB-231 breast cancer cells transfected with progesterone receptor complementary DNA. , 2003, The American journal of pathology.

[16]  G. Chetrite,et al.  Effect of Org OD14 (LIVIAL) and its metabolites on human estrogen sulphotransferase activity in the hormone-dependent MCF-7 and T-47D, and the hormone-independent MDA-MB-231, breast cancer cell lines. , 1999, Anticancer research.

[17]  Susanne Rosthøj,et al.  Competing risks as a multi-state model , 2002, Statistical methods in medical research.

[18]  P. Eiken,et al.  Compliance with 10 years oral hormonal replacement therapy. , 2002, Maturitas.

[19]  L. Holmberg,et al.  Prognostic characteristics in breast cancers after hormone replacement therapy , 2005, Breast Cancer Research and Treatment.

[20]  D. Winchester,et al.  Estrogen Replacement Therapy and Breast Cancer: Analysis of Age of Onset and Tumor Characteristics , 1999, Annals of Surgical Oncology.

[21]  M. Alkhalaf,et al.  Growth inhibition of MCF-7 human breast cancer cells by progesterone is associated with cell differentiation and phosphorylation of Akt protein , 2002, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[22]  B. V. VON Schoultz,et al.  Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. , 2002, American journal of obstetrics and gynecology.

[23]  J. Nesland,et al.  The Prognostic Impact of Hormone Receptors and c-erbB-2 in Pregnancy-Associated Breast Cancer and Their Correlation with BRCAI and Cell Cycle Modulators , 2003, International journal of surgical pathology.

[24]  P. Porter,et al.  Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. , 2003, JAMA.

[25]  R. Blamey,et al.  A prognostic index in primary breast cancer. , 1982, British Journal of Cancer.

[26]  E. Faragher,et al.  Hormone replacement therapy and tumour grade in breast cancer: prospective study in screening unit , 1996, BMJ.

[27]  R. Coates,et al.  Association of regimens of hormone replacement therapy to prognostic factors among women diagnosed with breast cancer aged 50-64 years. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[28]  H. Adami,et al.  Breast‐cancer risk following long‐term oestrogen‐ and oestrogen‐progestin‐replacement therapy , 1999, International journal of cancer.

[29]  M. Pike,et al.  Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. , 2000, Journal of the National Cancer Institute.

[30]  C. Agardh,et al.  A prospective study of different types of hormone replacement therapy use and the risk of subsequent breast cancer: the women's health in the Lund area (WHILA) study (Sweden) , 2003, Cancer Causes & Control.

[31]  A. Kavanagh,et al.  Duration of Hormone Replacement Therapy, Breast Tumour Size and Grade in a Screening Programme , 2003, Breast Cancer Research and Treatment.

[32]  M. Pike,et al.  Problems involved in including women with simple hysterectomy in epidemiologic studies measuring the effects of hormone replacement therapy on breast cancer risk. , 1998, American journal of epidemiology.

[33]  I. Ellis,et al.  Early-onset breast cancer--histopathological and prognostic considerations. , 1997, British Journal of Cancer.

[34]  Julian Peto,et al.  Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer , 1997, The Lancet.

[35]  N. Rasmussen,et al.  Use of hormone replacement therapy among Danish nurses in 1993 , 2000, Acta obstetricia et gynecologica Scandinavica.

[36]  R. Hoover,et al.  Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. , 2000, JAMA.

[37]  R. Langer,et al.  Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. , 2003, JAMA.

[38]  Valerie Beral,et al.  Breast cancer and hormone-replacement therapy in the Million Women Study , 2003, The Lancet.